New medicines agreements a boost for supply, sustainability: SHPA


Wednesday, 08 September, 2021

New medicines agreements a boost for supply, sustainability: SHPA

The Society of Hospital Pharmacists of Australia (SHPA) has welcomed the renewed five-year Strategic Agreements between the federal government and both the Generic Biosimilar Medicines Association (GBMA) and Medicines Australia as vital to protecting patients against medicines shortages and ensuring medicines are accessible, available and cost-efficient.

The Strategic Agreement with GBMA commits to requiring pharmaceutical companies to hold four to six months’ worth of critical medicines onshore, a policy called for by the hospital pharmacy sector to minimise disruption of care to Australia’s most unwell patients.

SHPA Chief Executive Kristin Michaels said the announcements by Health Minister Greg Hunt are a shot in the arm for Australia’s medicines supply and sustainability.

“SHPA brought the issue of medicines shortages to national attention through our 2017 report ‘Medicine shortages in Australia: A snapshot of shortages in Australian hospitals’, which prompted the legislation of a nationwide system for managing medicines supply on 1 January 2019, requiring mandatory reporting of medicines shortages by pharmaceutical companies,” Michaels said.

“On behalf of our members, who dedicate precious time to medicines shortage workarounds, we are very pleased to see the new GBMA agreement in place, which will help ensure hospital pharmacy teams are on the front foot managing supply issues well before they adversely affect any patients.”

Michaels said SHPA welcomes commitment to the first independent review of Health Technology Assessment in nearly 30 years, with hospital pharmacy poised to provide sharp insight.

“As custodians of 23% of annual Pharmaceutical Benefits Scheme (PBS) expenditure — which includes 75% of S100 Highly Specialised Drugs Program Expenditure and the majority of S100 Efficient Funding of Chemotherapy — hospital pharmacists have expansive scope to advise on the cost-effectiveness, safety and quality use of medicines in Australia.

“Today’s review announcement, as part of the Medicines Australia agreement, is timely given both National Medicines Policy and Pharmaceutical Reform Agreements are currently being reviewed.

“Most medicines newly added to the PBS are supplied by pharmacists in our hospitals and, even before they receive registration in Australia and are subsequently listed on the PBS, they are used in hospitals by pharmacists either as clinical trial medicines or unapproved medicines for patients with rare diseases, cancers and complex conditions.

“SHPA welcomes improved horizon scanning on this important sustainability issue, to ensure Australians continue to have access to the newest and most effective medicines available around the world to treat complex diseases and conditions, with hospital pharmacists by their side delivering crucial face-to-face services to enhance the safe and effective use of medicines at the bedside.”

Image credit: ©stock.adobe.com/au/DedMityay

Related News

The Royal Children's Hospital Melbourne trials COVID-19 nasal swab

The Murdoch Children's Research Institute and The Royal Children's Hospital Melbourne are...

IVF: success rates rise, multiple births fall

Advancements in laboratory techniques and improvements in the overall management of couples...

AI-powered imaging software begins market pilot

Artrya's non-invasive diagnostic support solution to detect coronary artery disease has...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd